PMID- 16699279
OWN - NLM
STAT- MEDLINE
DCOM- 20060831
LR  - 20151119
IS  - 0257-2753 (Print)
IS  - 0257-2753 (Linking)
VI  - 24
IP  - 1-2
DP  - 2006
TI  - Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.
PG  - 201-6
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) plays a pivotal role in the 
      pathogenesis of inflammatory bowel diseases and bone resorption as well. Limited 
      data exist about the effect of anti-TNF-alpha infliximab on bone metabolism in 
      inflammatory-type Crohn's disease (CD). AIM: Our aim was to evaluate the effect 
      of infliximab treatment on rapid changes of bone metabolism in fistulizing CD 
      patients. METHODS: 27 patients with fistulizing CD were treated with three series 
      of infliximab. Serum osteocalcin (OC) and beta-CrossLaps (bCL) were measured 
      before administration of each infliximab infusion. 54 patients with inactive CD 
      were controls. RESULTS: In treated patients, there were significant differences 
      in bCL concentrations on days 0 and 14 (p < 0.01) and days 0 and 42 (p < 0.05). 
      OC levels increased significantly between day 0 and 42 (p < 0.05). The values of 
      bCL and OC of control groups differed from serum levels in active patients before 
      the treatment, but not on day 42. Bone markers improved significantly in 
      responder patients, but not in non-responders. CONCLUSION: The beneficial effect 
      of infliximab to the bone metabolism is more expressive in patients whose 
      fistulizing disease improves with this therapy. Our results suggest that 
      TNF-alpha has an important role in the alteration of bone metabolism in 
      fistulizing CD patients.
CI  - Copyright 2006 S. Karger AG, Basel.
FAU - Miheller, Pal
AU  - Miheller P
AD  - Semmelweis University, Second Department of Internal Medicine, Budapest, Hungary. 
      mihpal@yahoo.co.uk
FAU - Muzes, Gyorgyi
AU  - Muzes G
FAU - Zagoni, Tamas
AU  - Zagoni T
FAU - Toth, Miklos
AU  - Toth M
FAU - Racz, Karoly
AU  - Racz K
FAU - Tulassay, Zsolt
AU  - Tulassay Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Switzerland
TA  - Dig Dis
JT  - Digestive diseases (Basel, Switzerland)
JID - 8701186
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal/administration & dosage/*therapeutic use
MH  - Bone Density/*drug effects
MH  - Bone Resorption/*drug therapy/etiology/metabolism
MH  - Crohn Disease/complications/*drug therapy/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Gastrointestinal Agents/administration & dosage/*therapeutic use
MH  - Humans
MH  - Infliximab
MH  - Infusions, Intravenous
MH  - Intestinal Fistula/complications/*drug therapy/metabolism
MH  - Male
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2006/05/16 09:00
MHDA- 2006/09/01 09:00
CRDT- 2006/05/16 09:00
PHST- 2006/05/16 09:00 [pubmed]
PHST- 2006/09/01 09:00 [medline]
PHST- 2006/05/16 09:00 [entrez]
AID - 91299 [pii]
AID - 10.1159/000091299 [doi]
PST - ppublish
SO  - Dig Dis. 2006;24(1-2):201-6. doi: 10.1159/000091299.